AMPI

Location:MA, US
Speaker:Trevor Castor
Title:CEO
Primary Industry:Pharma & Biotech
Executive Summary:AMPI is developing nontoxic Vitamin D therapeutics for prostate cancer and other medical indications such as osteoporosis and multiple sclerosis. Recently, the National Cancer Institute awarded AMPI’s collaborators – Boston University Medical School, Boston, MA and Aphios Corporation, Woburn, MA a Phase I STTR grant to initiate development of nanosomal formulation of a nontoxic Vitamin D analog for hormone refractory prostate cancer. Inverse relationships between incidence and mortality from various cancers, autoimmune and other diseases and dietary vitamin D are well-established. While the vitamin D hormone has strong anticancer effect in cancer cells, it is highly toxic at therapeutic doses. In vitro tests of a bromoacetate analog of the vitamin D hormone (AMPI-109) has been shown to have increased the anticancer effect while reducing systemic toxicity. This occurs through alkylation of the ligand-binding domain of vitamin D receptor in tumor cells. Furthermore, preliminary in vivo studies showed that AMPI-109 strongly reduces androgen-refractory prostate cancer in a mouse xenograft model. Nanosomal formulation of AMPI-109 is being used to further reduce systemic toxicity, increase circulatory half-life and efficacy of AMPI-109 in prostate cancer.
Venture is:A-Round

HIGHLIGHTS

Merck
Corporate Symposium

Harvard OTD
Partner Sponsor

2008 Corporate Presentations

Air Products
Boeing
BP
Cabot
Honda
Kodak
Medtronic
Merck
  • BASF
  • Genzyme
  • Lockheed Martin
  • Sanyo

Event Sponsors

Univalor
AzTE
Jackson Walker

Collocated Events

June 1-5, 2008
Nanotech 2008
Clean Technology 2008
BioNano 2008

Press Sponsor

Business Wire

Commercialization Partner

BusinessWeek

Media Sponsors

(joint with Nanotech 2008) Nature
Science
Red Herring

Supporting Organizations

Boston University
Midwest Research University Network
piribo

 

“A major challenge for both the technology and the financial communities is finding a forum in which all parties can interact and explore possibilities for future innovation. TechConnect was created to fill this void, bringing both sides together under one roof into a setting that ultimately will help significant ground-breaking concepts come to life.”
 
Matthew Laudon, Co-Founder and Director of TechConnect